The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.

Authors

Feng Cheng
Yonghua Xu (ORCID: https://orcid.org/0000-0002-3632-8900)
Jianhua Rao (ORCID: https://orcid.org/0000-0003-1222-7707)
S. Wang (ORCID: https://orcid.org/0009-0009-6355-6421)
Long Zhang (ORCID: https://orcid.org/0000-0001-8139-0474)
Hongwei Zhang (ORCID: https://orcid.org/0000-0002-6405-5399)
Feng Zhang (ORCID: https://orcid.org/0000-0003-4556-8276)
Xinhua Zhu
Xuehao Wang (ORCID: https://orcid.org/0000-0002-6050-3385)
Xin Wei

Institutions

Xuzhou Medical College (CN)
Nantong University (CN)
Huaian First People’s Hospital (CN)
Nanjing Drum Tower Hospital (CN)
Yancheng First People's Hospital (CN)
Jiangsu Cancer Hospital (CN)
Jiangsu Province Hospital (CN)
Nanjing Medical University (CN)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-05-28
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.4134
Primary Topic: Hepatocellular Carcinoma Treatment and Prognosis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.

Feng Cheng, Yonghua Xu, Jianhua Rao, S. Wang et al.

May 28, 2025

Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and Prognosis

article

The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.

Feng Cheng, Yonghua Xu, Jianhua Rao, S. Wang, Long Zhang, Hongwei Zhang, Feng Zhang, Xinhua Zhu, Xuehao Wang, Xin Wei

May 28, 2025article en

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(16_suppl)

Xuzhou Medical College (CN), Nantong University (CN), Huaian First People’s Hospital (CN), Nanjing Drum Tower Hospital (CN), Yancheng First People's Hospital (CN), Jiangsu Cancer Hospital (CN), Jiangsu Province Hospital (CN), Nanjing Medical University (CN)

Openalex Percentile: Top 82%

Hepatocellular Carcinoma Treatment and Prognosis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study. — Feng Cheng, Yonghua Xu, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS